Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADH1A | P07327 | 3/20 | 0.50 |
| ▸ | ADH1C | P00326 | 2/20 | 0.47 |
| ▸ | DRD3 | P35462 | 7/20 | 0.39 |
| ▸ | DRD2 | P14416 | 5/20 | 0.39 |
| ▸ | DRD4 | P21917 | 4/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3373144 | 0.98 | ADH1A (0.48) | ADH1AADH1CDRD3DRD2DRD4 | |
| SCHEMBL17439391 | 0.93 | ADH1A (0.48) | ADH1AADH1CDRD3DRD2DRD4 | |
| SCHEMBL516269 | 0.90 | ADH1A (0.54) | ADH1AADH1CDRD3DRD2DRD4 | |
| SCHEMBL11073680 | 0.90 | ADH1A (0.54) | ADH1AADH1CDRD3DRD2DRD4 | |
| SCHEMBL22541111 | 0.90 | ADH1A (0.54) | ADH1AADH1CDRD3DRD2DRD4 | |
| SCHEMBL3370178 | 0.87 | — | — | |
| SCHEMBL516016 | 0.87 | ADH1A (0.52) | ADH1AADH1CDRD3DRD2DRD4 | |
| SCHEMBL629781 | 0.86 | ADH1A (0.42) | ADH1AADH1CDRD3DRD2DRD4 | |
| SCHEMBL22536991 | 0.86 | ADH1A (0.42) | ADH1AADH1CDRD3DRD2DRD4 | |
| SCHEMBL23073672 | 0.85 | ADH1A (0.50) | ADH1AADH1CMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024042246-A1 | PROCESS FOR THE PREPARATION OF A BENZENE DERIVATIVE | MELETIOS THERAPEUTICS (FR) | 2024-02-29 | — | — | WO | disclosed |
| EP-3599236-B1 | ARYLMETHOXY ISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORP (US) | 2023-08-23 | — | — | EP | disclosed |
| US-11072632-B2 | Inhibitors of 17β-HSD1, 17β-HSD3 and 17β-HSD10 | UNIVERSITé LAVAL (CA) | 2021-07-27 | — | — | US | disclosed |
| EP-3059238-B1 | FUSED HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION, AND USES THEREOF | SHANGHAI YINGLI PHARM CO LTD (CN) | 2020-05-27 | — | — | EP | disclosed |
| WO-2018045084-A1 | TETRACYCLINE COMPOUNDS AND METHODS OF TREATMENT | TETRAPHASE PHARMACEUTICALS, INC. (US) | 2018-03-08 | — | — | WO | disclosed |
| EP-2427425-B1 | TETRACYCLINE COMPOUNDS | TETRAPHASE PHARMACEUTICALS INC (US) | 2017-03-08 | — | — | EP | disclosed |
| US-9315451-B2 | Tetracycline compounds | TETRAPHASE PHARMACEUTICALS, INC. (US) | 2016-04-19 | — | — | US | disclosed |
| US-20140088053-A1 | INHIBITORS OF 17Beta-HSD1, 17Beta-HSD3 AND 17Beta-HSD10 | UNIVERSITé LAVAL (CA) | 2014-03-27 | — | — | US | disclosed |
| US-20140088053-A1 | INHIBITORS OF 17Beta-HSD1, 17Beta-HSD3 AND 17Beta-HSD10 | UNIVERSITé LAVAL (CA) | 2014-03-27 | — | — | US | disclosed |
| US-20120208829-A1 | 2-PHENOXY PYRIMIDINONE ANALOGUES | NEUROGEN CORPORATION (US) | 2012-08-16 | — | — | US | disclosed |
| US-7795262-B2 | Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues | NEUROGEN CORPORATION (US) | 2010-09-14 | — | — | US | disclosed |
| US-20100216763-A1 | Heteroaryl Amide Derivatives | H. LUNDBECK A/S (DK) | 2010-08-26 | — | — | US | disclosed |
| US-20090069347-A1 | 2-phenoxy pyrimidinone analogues | NEUROGEN CORPORATION (US) | 2009-03-12 | — | — | US | disclosed |
| US-20080247964-A1 | SUBSTITUTED AZASPIRO DERIVATIVES | NEUROGEN CORPORATION | 2008-10-09 | — | — | US | disclosed |
| US-20080175794-A1 | Substituted Pyridazinyl- and Pyrimidinyl-Quinolin-4-Ylamine Analogues | NEUROGEN CORPORATION (US) | 2008-07-24 | — | — | US | disclosed |
| US-20080124384-A1 | Heteroaryl Substituted Piperazinyl-Pyridine Analogues | NEUROGEN CORPORATION | 2008-05-29 | — | — | US | disclosed |
| US-20080051387-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES | NEUROGEN CORPORATION | 2008-02-28 | — | — | US | disclosed |
| US-20070232591-A1 | Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues | NEUROGEN CORPORATION | 2007-10-04 | — | — | US | disclosed |
| US-20070078135-A1 | Substituted heteroaryl CB1 antagonists | NEUROGEN CORPORATION (US) | 2007-04-05 | — | — | US | disclosed |
| US-5703112-A | Method of preventing emesis using tetrahydrobenz CD!indole-6-carbonxamides | ELI LILLY AND COMPANY (US) | 1997-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051387-A1 | TETRAHYDROPYRIDO[3,4-D]PYRIMIDINES AND RELATED ANALOGUES | HRH3, HRH4, HRH2 | ADH1A 1104/4885ADH1C 1424/4885DRD3 409/4885 |
| US-20080247964-A1 | SUBSTITUTED AZASPIRO DERIVATIVES | HRH3, HRH4, HRH1 | ADH1A 606/4885ADH1C 1355/4885DRD3 840/4885 |
| US-20070232591-A1 | Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues | HRH3, HRH4, HRH1 | ADH1A 1040/4885ADH1C 1140/4885DRD3 465/4885 |
| US-11072632-B2 | Inhibitors of 17β-HSD1, 17β-HSD3 and 17β-HSD10 | HSD17B11, HSD17B3, HSD17B1 | ADH1A 97/4885ADH1C 67/4885DRD3 923/4885 |
| US-20070078135-A1 | Substituted heteroaryl CB1 antagonists | CNR1, CNR2, OPRL1 | ADH1A 486/4885ADH1C 587/4885DRD3 209/4885 |
| US-20140088053-A1 | INHIBITORS OF 17Beta-HSD1, 17Beta-HSD3 AND 17Beta-HSD10 | HSD17B11, HSD17B1, HSD17B3 | ADH1A 129/4885ADH1C 82/4885DRD3 1422/4885 |
| US-20100216763-A1 | Heteroaryl Amide Derivatives | HCAR2, PIGS, GPR52 | ADH1A 1321/4885ADH1C 2612/4885DRD3 1413/4885 |
| US-20120208829-A1 | 2-PHENOXY PYRIMIDINONE ANALOGUES | GPR174, GPR17, PTGFR | ADH1A 1626/4885ADH1C 1993/4885DRD3 2595/4885 |
| US-20080124384-A1 | Heteroaryl Substituted Piperazinyl-Pyridine Analogues | PIGO, GPR52, GPR88 | ADH1A 1710/4885ADH1C 2529/4885DRD3 2302/4885 |
| US-20090069347-A1 | 2-phenoxy pyrimidinone analogues | GPR174, GPR17, PTGFR | ADH1A 1626/4885ADH1C 1993/4885DRD3 2595/4885 |
| US-20080175794-A1 | Substituted Pyridazinyl- and Pyrimidinyl-Quinolin-4-Ylamine Analogues | PIGS, HRH4, GPR68 | ADH1A 3078/4885ADH1C 3946/4885DRD3 2229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.